AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm
BMS, headquartered in Princeton, New Jersey, and known for its cancer treatments, was worth $133bn £98bn
- Center-left2
- Center1
no rewrites detected — all voices distinct
Summary
BMS, headquartered in Princeton, New Jersey, and known for its cancer treatments, was worth $133bn £98bn . AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm. $400bn tie-up with Bristol Myers Squibb would create world’s fourth largest drugmaker but analysts question rationale for deal More than £17bn was wiped off the value of Britain’s biggest drugmaker, AstraZeneca, on Monday after a report that it was in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near $400bn £300bn pharmaceutical group. AstraZeneca, run by Pascal Soriot, its longtime chief executive, had been worth nearly £196bn before the news broke.
Furthermore, AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal.
Cross-referenced from 3 sources.
Factual coreconfirmed by several independent voices
BMS, headquartered in Princeton, New Jersey, and known for its cancer treatments, was worth $133bn £98bn .
reliability moderate2/2 sourcesAstraZeneca shares fall 8.9% over merger talks with US cancer drug firm. $400bn tie-up with Bristol Myers Squibb would create world’s fourth largest drugmaker but analysts question rationale for deal More than £17bn was wiped off the value of Britain’s biggest drugmaker, AstraZeneca, on Monday after a report that it was in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near $400bn £300bn pharmaceutical group.
reliability moderate2/2 sourcesAstraZeneca, run by Pascal Soriot, its longtime chief executive, had been worth nearly £196bn before the news broke.
reliability moderate2/2 sources
Reported detailssecondary facts, each attributed to its source
AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal.
according to Investing.com
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
BMS, headquartered in Princeton, New Jersey, and known for its cancer treatments, was worth $133bn £98bn .
omitted byCentercovered byLeft sideAstraZeneca shares fall 8.9% over merger talks with US cancer drug firm. $400bn tie-up with Bristol Myers Squibb would create world’s…
omitted byCentercovered byLeft sideAstraZeneca, run by Pascal Soriot, its longtime chief executive, had been worth nearly £196bn before the news broke.
omitted byCentercovered byLeft side
Sources2 sources cross-checked
Center-left1
Center1
